Navigation Links
Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- BioReliance, a leading provider of global biopharmaceutical testing services, announced today that it has agreed to be acquired by Sigma-Aldrich Corporation (NASDAQ: SIAL).  Avista Capital Partners, the majority owner of BioReliance Holdings, Inc., agreed to sell the company for $350 million in cash.  The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

BioReliance provides critical services that include biologics testing, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science clients worldwide.  BioReliance's service offering helps facilitate drug development, manufacturing and commercialization activities.  The Company's ability to develop and execute global testing protocols in compliance with various regulatory standards enables BioReliance's clients to register products with regulatory agencies worldwide.

Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.

Commenting on the transaction, BioReliance's President and CEO Charles Harwood stated, "The acquisition of BioReliance by Sigma-Aldrich creates one of the broadest product and service offerings for the development and manufacture of biological drugs.  In addition, BioReliance's Specialized Toxicology and Animal Health Services segments are complementary to other Sigma-Aldrich product and technology areas."

Avista Capital Partners acquired BioReliance in 2007.  With regards to the acquisition of BioReliance by Sigma-Aldrich, Avista Partner and President David Burgstahler commented
'/>"/>

SOURCE BioReliance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
4. Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years
5. IsZo Capital Writes to Taro Pharmaceutical Board Commenting on Management Proposals for 2011 Annual Shareholder Meeting; Reflecting on Sun Pharmas Response to Similar 2009 Proposals
6. IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders Meeting
7. Physicians Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX
8. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
9. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
10. WestPark Capital Announces $2.6 Million IsoRay Offering
11. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Therapeutics,(Amex: CXM ) and its operating ... from a preclinical study, demonstrating a new ... for the potential,treatment of acute myocardial infarction ... Central (BMC) Cardiovascular Disorders (2008, 8:7, April,10, ...
... Regimen Designed to Avoid Risk of Toxicity ... Associated with Nucleoside Class of HIV Drugs, ... ) today announced that it has initiated a Phase ... in first-line therapy of adult treatment-naive HIV-infected patients,with R5-type ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
(Date:8/20/2014)... By Barbara Bronson Gray ... News) -- Although it,s extremely rare, colds, flu and ... of elevated risk for stroke in children, a new study ... have a stroke in the United States, said Dr. Heather ... neurology and pediatrics at the University of California, San Francisco ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... long been an option, but a new study shows that ... most common reasons women didn,t undergo reconstruction was that they ... or they were focused on their cancer treatment," said lead ... Sloan Kettering Cancer Center, in New York City. Also ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... treating cancer - using Botox. A study presented in ... shows that cancer growth could be suppressed by ... to cancer stem cells. The approach thus treated the ... safe and efficient. The researchers have thus far tested ... on humans. , The nervous system is crucial in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... University of Pittsburgh School of Medicine. , ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... July 10 Life is unfair, the economy is out ... true these statements might be, your ability to bounce back ... In his refreshing new self-help book, "Controlling Your Future: Six ... ), Richard Norgaard shows readers how to achieve total ...
... , , , , MARIETTA, Ga., July ... business executives that the top healthcare cost drivers for employers ... online webinar, hosted by Source Media, showed that lost workplace ... costly to employers. The purpose of the webinar was to ...
... Recently, students attended ... Anatomy 200 module of their Massage Therapy program at CNI College prepared them for a ... focus in this module. , ... Orange, CA (PRWEB) July 10, 2009 -- Recently, students attended a lab at a local ...
... ... can keep playing after shoulder joint replacement , ... Keystone, CO (Vocus) July 10, 2009 -- Replacing a joint in any ... not being able to return to a sport or activity. However, a new study presented ...
... A ... Hospital. , ... 2009 -- A Washington County woman is recovering well today after undergoing a new, robot-assisted ... is one of just a handful of bariatric patients in the region to benefit from ...
... July 9 Amgen (Nasdaq: AMGN ) announced ... Henderson, Ph.D., to the Company,s Board. Dr. Henderson, 48, ... School , having been the Eastman Kodak LFM Professor of ... MIT ) Sloan School since 1999. She specializes in technology ...
Cached Medicine News:Health News:'Controlling Your Future: Six Steps To A Better Life': New Self-Help Book Teaches the Art of Self-discipline, Self-control 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 3Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 4Health News:CNI College Massage Therapy Students Experience Plastination & Cadaver Lab 2Health News:Shoulder Surgery Doesn't Prevent Return to Sports, According to New Study presented at AOSSM Annual Meeting 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 3Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 4Health News:Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors 2
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: